4th iPSC Drug Development and Manufacturing Summit

Memo

With Kenai Therapeutics emerging from stealth with an $82 Million Series A funding round, 2024 has started strong for iPSC drug developers looking to showcase the potential of their pipelines ahead of the next wave of investment. The 4th iPSC Drug Development and Manufacturing Summit is your longest standing and definitive iPSC focused industry platform showcasing cutting-edge advances across R and D through to manufacturing and analytical development to help you stay at the forefront of the iPSC cell therapy revolution. With content split across our Research and Development and Manufacturing and Analytical Development tracks, this is the one-stop shop meeting for drug developers and academic thought leaders looking to streamline their route to the clinic and scale up their manufacturing processes. URLs:Tickets: https://go.evvnt.com/2453698-2?pid=5569Brochure: https://go.evvnt.com/2453698-3?pid=5569 Date and Time: Tuesday, 01 October 2024 at 08:00 to Thursday, 03 October 2024 at 17:00 Venue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States Prices:Conference + 2 Workshops - Drug Developer Pricing : USD 4197.00,Conference + 1 Workshop - Drug Developer Pricing: USD 3598.00,Conference Only - Drug Developer Pricing: USD 2999.00,Conference + 2 Workshops - Solution Provider Pricing: USD 5097.00,Conference + 1 Workshop - Solution Provider Pricing: USD 4398.00,Conference Only - Solution Provider Pricing: USD 3699.00,Conference + 2 Workshops - Academic Pricing: USD 3597.00,Conference + 1 Workshop - Academic Pricing: USD 3098.00,Conference Only - Academic Pricing: USD 2599.00 Speakers: Allen Feng, Founder and Chief Scientific Officer, HebeCell, Anne Plant, Fellow Chief, Biosystems and Biomaterials Division, National Institute of Standards and Technology (NIST), Annelise Bennaceur, Chief Scientific Officer, iPSirius, Bruna Paulsen, Director - Manufacturing and Quality Control, Gameto, Chong Luo, Director, Cell Therapy, Tome Biosciences, Chris Barkey, Chief Executive Officer, Swissfinity, David Rodgers, Senior Director - Macrophage Cell Therapy, Shoreline Biosciences, Dhruv Sareen, Associate Professor and Executive Director - Biomanufacturing Center and Induced Pluripotent Stem Cell, Cedars-Sinai Medical Center, Dongsheng Guo, Instructor, UMass Chan Medical School, Harshyaa Makhija, Dean's Postdoctoral Fellow, Nanyang Technological University, Howard Federoff, Chief Medical Officer, Kenai Therapeutics, Jason Mills, Director - Process Development, Century Therapeutics, Joseph Wu, Professor and Director, Co-Founder, Stanford Cardiovascular Institute, Greenstone Biosciences, Kevin D’Amour, Chief Scientific Officer, Stemson Therapeutics LLC, Laura Koivusalo, CEO, StemSight Oy, Leonardo Velazco Cruz, Senior Scientist, Thymmune Therapeutics, Matt Angel, Chief Executive Officer, Factor Biosciences, Matt Moran, Senior Associate Development Engineer, Bayer, Michael Naso, Vice President, Century Therapeutics, Nicholas Wisniewski, Vice President of Data Science and BioInformatics, Stemson Therapeutics LLC, Rajneesh Jha, Associate Principal Scientist, AstraZeneca, Sherry Hikita, Director - Cell Therapy Research and Development Project, Novo Nordisk, Takehiko Kaneko, Chief Medical Officer, Head of Research and Development, Heartseed Inc, Wei Li, CSO, Cytovia Therapeutics, Will Ansari, Associate Director - Technology Development, Aspen Neuroscience, Zhu Pirot, Director and Technical Leader, Platform CGT Analytical Development, Bayer